1 / 7

Emixustat Macular Edema Market Analysis and Forecast to 2023

RnRMarketResearch.com adds “Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023”to its store. Emixustat hydrochloride (formerly known as ACU-4429) is an orally-dosed VCM that is designed to be selective for rod photoreceptors and is being developed for the treatment of GA associated with dAMD.

rudrak123
Download Presentation

Emixustat Macular Edema Market Analysis and Forecast to 2023

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 By RnRMarketResearch Browse more reports on Pharmaceuticals athttp://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  2. Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Emixustat hydrochloride (formerly known as ACU-4429) is an orally-dosed VCM that is designed to be selective for rod photoreceptors and is being developed for the treatment of GA associated with dAMD. This was the first internally-developed compound by Acucela, a Seattle-based biotechnology company. Acucela has one issued US patent (No. 7,982,071) and seven pending US patents for emixustat, all of which will expire in or around 2029. Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  3. Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Complete Report is available at http://www.rnrmarketresearch.com/emixustat-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html . ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  4. Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Scope: Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Emixustat including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Emixustat for the top country from 2013 to 2023. Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  5. Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Reasons to Buy: • Understand and capitalize by identifying products that are most likely to ensure a robust return. • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration. • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential. • Make more informed business decisions from insightful and in-depth analysis of Emixustat performance. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  6. Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 Table of Contents: 1.1 List of Tables 81.2 List of Figures 92 Introduction 102.1 Related Reports 113 Disease Overview 133.1 Macular Degeneration Overview 133.1.1 Etiology and Pathophysiology 153.1.2 Classification 193.1.3 Symptoms and Diagnosis 213.2 Macular Edema Overview 24 ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

  7. Emixustat (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023 For more details contact Mr. Ritesh Tiwari :sales@rnrmarketresearch.com/ +18883915441 RnRMarkertResearch RnRMarketResearch.com, an online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RnRMarket Research library has syndicated reports by leading market research  publishers across the globe. ©http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441

More Related